Free Trial

TScan Therapeutics (NASDAQ:TCRX) Receives "Outperform" Rating from Wedbush

TScan Therapeutics logo with Medical background

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reiterated by Wedbush in a research report issued to clients and investors on Tuesday,RTT News reports. They currently have a $7.00 price target on the stock. Wedbush's price objective would suggest a potential upside of 444.75% from the stock's previous close. Wedbush also issued estimates for TScan Therapeutics' Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.91) EPS.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Needham & Company LLC reissued a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays cut their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $8.50.

View Our Latest Report on TCRX

TScan Therapeutics Price Performance

TCRX stock traded down $0.10 during trading on Tuesday, reaching $1.29. 244,572 shares of the company were exchanged, compared to its average volume of 362,468. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market capitalization of $72.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.06. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69. The company has a 50-day moving average of $1.49 and a two-hundred day moving average of $2.70.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analysts' expectations of $1.62 million. As a group, equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics during the fourth quarter worth $32,000. ProShare Advisors LLC acquired a new stake in TScan Therapeutics in the fourth quarter worth about $40,000. Wells Fargo & Company MN grew its position in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock worth $59,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at $59,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Company Profile

(Get Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Recommended Stories

Analyst Recommendations for TScan Therapeutics (NASDAQ:TCRX)

Should You Invest $1,000 in TScan Therapeutics Right Now?

Before you consider TScan Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.

While TScan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines